TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance

Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the recent 222,000 share purchase by ARK Investment as a signal of growing institutional confidence, which can support a premium valuation multiple relative to peers.
They expect that increased institutional sponsorship could improve liquidity and reduce share price volatility, making the stock more attractive to additional long term holders.
Positive sentiment around 10x Genomics product roadmap and technology leadership is seen as a driver of sustained revenue growth, helping to justify upward revisions to long term margin assumptions.
Stronger buy side interest is interpreted as validation that near term execution risks are manageable, reinforcing the case for a gradual re rating of the shares as growth normalizes at higher levels.

Bearish Takeaways

Bearish analysts caution that concentrated buying from a high profile fund may temporarily inflate the share price, potentially disconnecting it from near term fundamentals.
They highlight that the company still needs to demonstrate consistent profitability and operating leverage to fully support the higher fair value estimate suggested by recent target hikes.
There are concerns that any slowdown in instrument placements or consumables pull through could pressure growth assumptions that are now embedded in more optimistic valuation models.
Some remain wary that reliance on a narrow set of flagship products leaves the company exposed to competitive innovations, which could compress future growth rates and multiples if execution falters.

What's in the News

Cathie Wood's ARK Investment Management purchased 222,000 shares of 10x Genomics, signaling renewed institutional interest in the stock (periodical).
10x Genomics launched the next generation Flex assay with automation compatible plate based multiplexing, enabling cost effective single cell analysis at up to 384 samples and 100 million cells per week (key development).
The company announced ASTRA, a major Asia Pacific collaboration with the Garvan Institute and the University of Tokyo to build a pan cancer spatial atlas using the Xenium platform, aiming to improve precision oncology for underrepresented populations (key development).
10x Genomics provided fourth quarter 2025 revenue guidance of 154 million dollars to 158 million dollars, implying a 6 percent year over year decline but 5 percent sequential growth at the midpoint (key development).
A new collaboration with Anthropic will integrate 10x analysis tools into Claude for Life Sciences via the Model Context Protocol, allowing researchers to run single cell and spatial analyses through natural language instead of code (key development).

Valuation Changes

The fair value estimate has risen slightly from approximately 16.57 dollars to 17.36 dollars per share, reflecting a modest upward revision to intrinsic value.
The discount rate has edged up marginally from about 7.80 percent to 7.81 percent, indicating a nearly unchanged view of risk and required return.
Revenue growth assumptions have been reduced slightly from roughly 3.20 percent to 2.92 percent, signaling a more cautious outlook on top line expansion.
The net profit margin has improved modestly from about 15.50 percent to 15.66 percent, incorporating expectations for slightly better long term profitability.
The future P/E multiple has increased from roughly 26.6 times to 27.8 times, suggesting a somewhat higher valuation multiple applied to forward earnings.

Expansion of product offerings and strategic acquisitions are enhancing innovation, reducing operational costs, and solidifying leadership in advanced genomics tools.
Growth in global partnerships and improved international presence are increasing market opportunities and supporting resilient, long-term revenue streams.
Macroeconomic pressures, shrinking pricing power, product shifts, and ongoing losses are undermining revenue growth, margin stability, and the path to profitability.

Catalysts

About 10x Genomics

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.
Recent and upcoming product launches-including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein-are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.
The acquisition of Scale Biosciences broadens 10x Genomics' technical capabilities in single-cell analysis, allowing integration of foundational innovations like combinatorial indexing and quantum barcoding, which may accelerate innovation, reduce costs, and open up new high-value markets, positively impacting future revenue growth and margins.
Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements-which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.
Strengthening international distribution, particularly improved execution in China and Europe, together with strategic responses to tariff and CapEx headwinds, helps 10x diversify regional risks and access untapped markets, enhancing revenue growth resilience despite the currently challenging US academic funding environment.

10x Genomics Earnings and Revenue Growth

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming 10x Genomics's revenue will grow by 2.2% annually over the next 3 years.
Analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -13.1% to the average US Life Sciences industry of 14.2% in 3 years.
If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $97.8 million (and earnings per share of $0.72) by about September 2028, up from $-84.6 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 25.7x on those 2028 earnings, up from -19.6x today. This future PE is lower than the current PE for the US Life Sciences industry at 29.1x.
Analysts expect the number of shares outstanding to grow by 2.84% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

10x Genomics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing macroeconomic and funding uncertainty, especially in the US and Europe, is dampening academic and government research budgets, leading to conservative spending, extended project timelines, delays in equipment purchases, and heightened price sensitivity-directly pressuring future revenue growth and earning stability.
Lower average selling prices and continued discounting of instruments (notably Chromium and spatial platforms) to address customers' CapEx constraints indicate shrinking pricing power and may compress gross margins over time, especially as capital spending headwinds persist.
Product transitions to lower-cost solutions (e.g. GEM-X Flex, Flex v2, and Scale Biosciences' combinatorial indexing), while driving higher reaction volumes, are creating a near-term headwind to consumables revenue growth, as price declines are not yet fully offset by increased volume, risking overall revenue and operating leverage.
Temporary boosts in key geographies (such as APAC/China) from one-off events like tariff-related pull forwards may not be sustainable, while geopolitical risks and possible export restrictions could impact international expansion potential and geographically diversify revenue streams.
Persistent operating losses (excluding one-off gains from litigation settlements) and the need for ongoing cost discipline in R&D and SG&A suggest that, despite cash reserves, the business remains vulnerable to weaker top-line performance and delayed return to profitability-making net earnings recovery uncertain in a prolonged challenging environment.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $15.077 for 10x Genomics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $17.0, and the most bearish reporting a price target of just $13.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $688.4 million, earnings will come to $97.8 million, and it would be trading on a PE ratio of 25.7x, assuming you use a discount rate of 7.2%.
Given the current share price of $13.34, the analyst price target of $15.08 is 11.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on 10x Genomics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advanced Genomics Tools Will Shape Future Precision Medicine